Late treatment study
et al., National Science Review, nwaa113, doi:10.1093/nsr/nwaa113 (Peer Reviewed)
Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of ch loroquine for the treatment of COVID-19
Q patients, 176 control. Mean time to undetectable viral RNA and duration of fever significantly reduced. No serious adverse events.
time to viral-, ↓67.0%, p<0.0001
Please send us corrections, updates, or comments.